“We have determined that we need to conduct additional preclinical studies, optimize our manufacturing processes, and most importantly to generate decisive scientific data regarding the prolonged functionality and therapeutic benefits of our liver tissue patch,” said Taylor J. Crouch, CEO, Organovo.
Those with a long memory may know that Crouch was the CEO of Variagenics.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”